+1 915 229 3004 (U.S.) | 
+44 7452 242832 (U.K.)
+1 915 229 3004 (U.S.) | +44 7452 242832 (U.K.)
Global Remdesivir (COVID-19) Market Size was valued at USD 5.7 Billion in 2022. The Remdesivir (COVID-19) market industry is projected to grow from USD 5.8 Billion in 2023 to USD 10.80 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.80% during the forecast period (2023 - 2032). A medicine that can be used to treat people with severe COVID-19 symptoms is urgently needed, are the key market drivers enhancing the market growth.
Download Free Sample to learn more about this report.
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
Among other businesses, the COVID-19 outbreak has had a considerable influence on the pharmaceutical industry. A key factor in this market rise has been the urgent need for effective medications to combat the virus. Remdesivir appeared as a promising therapeutic option for COVID-19 patients, and it was one of the drugs that gained interest at the time and assisted in its market expansion. First and foremost, the magnitude and severity of the COVID-19 epidemic have resulted in an enormous need for treatments. As the virus quickly spread over the globe, stressing healthcare systems and increasing hospitalizations, there was an urgent need for drugs that could cure symptoms, reduce hospital stays, and perhaps even improve patient outcomes. Due to its positive results in clinical trials, remdesivir has received a lot of attention as a potential treatment. Strong demand brought on by the global health crisis had a significant role in Remdesivir's quick market growth.
The efficacy and safety profile of Remdesivir was another factor driving the market. Patients with COVID-19 responded well to remdesivir in both clinical trials and real-world settings. This shorter hospital stay may have improved patient outcomes by reducing the risk of problems brought on by prolonged hospital stays, which also lessened the burden on healthcare systems. The positive clinical results and Remdesivir's capacity to meet a demand in medicine contributed to its commercial success. Furthermore, regulatory approvals had a big impact on Remdesivir's market. As the pandemic spread, international regulatory organizations sped up their evaluation processes to consider potential COVID-19 medications. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both awarded Remdesivir emergency use authorizations and subsequent clearances. Due to the widespread usage of Remdesivir made possible by these authorizations and approvals, the market was able to grow.
Government financing and programs significantly supported Remdesivir's commercial expansion. As soon as it became clear that effective treatments were urgently needed to combat the COVID-19 outbreak, governments all around the world initiated a variety of efforts. These programs provided financing for the creation and acquisition of potential medications like Remdesivir. Government funding has hastened the availability and accessibility of Remdesivir, which has increased market demand.
The dynamics of Remdesivir's market are also impacted by its pricing and reimbursement policies. The pricing decisions made by Gilead Sciences and the reimbursement rules of both public and private healthcare systems have an impact on the drug's availability and demand. Due to pricing agreements and reimbursement schemes developed by governments and healthcare systems to guarantee the drug's accessibility and affordability, Remdesivir's market expanded. As a result, a number of interconnected factors associated to the COVID-19 pandemic have contributed to the growth of the Remdesivir industry. The urgent need for effective treatments, Remdesivir's shown efficacy and safety profile, regulatory approvals, governmental initiatives and funding, price and reimbursement policies, and pricing and reimbursement policies have all considerably increased demand for the drug. The dynamics of Remdesivir may have altered since my previous knowledge update in September 2021, and it's important to remember that market situations can change swiftly. It is recommended to consult latest market research and industry studies from reliable sources for the most accurate and up-to-date information. Thus, driving the Remdesivir (COVID-19) market revenue.
The global Remdesivir (COVID-19) market segmentation, based on dosage includes 5mg, 10mg, 50mg, and 100mg. With 40.65% of market revenue coming from the 100mg sector, this segment led the market. An increasing number of people in emerging nations are becoming overweight, and consumer awareness of low-calorie beverages is rising.
The global Remdesivir (COVID 19) market segmentation, based on distribution channel, includes Hospitals, Drug stores, others. The category with the highest income was Hospitals (55.36%). The sector is growing as a result of the abundance of weight reduction products in department stores, pharmacies, spas, and salons. An "ecosystem" is a group of individuals who work together in the building industry. Store-based channels also continuously help to improve overall customer engagement and experience in stores.
Download Free Sample to learn more about this report.
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
Insights into the markets in North America, Europe, Asia-Pacific, and the rest of the world are provided by the study. The North America Remdesivir (COVID-19) Market dominated this market in 2022 (45.80%). This is brought on by the sharp rise of COVID-19 cases, the prevalence of diseases, the accessibility, and the sizable presence of major market rivals in this region. Further, In the North American area, the U.S. Remdesivir (COVID-19) market had the biggest market share, while the Canada Remdesivir (COVID 19) market had the quickest rate of expansion.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Download Free Sample to learn more about this report.
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
Europe Remdesivir (COVID 19) market accounts for the second-largest market share. This is because the number of COVID-19 patients has increased. Further, In the European region, the German Remdesivir (COVID 19) market had the biggest market share, and the U.K. Remdesivir (COVID-19) market had the quickest rate of growth.
The Asia-Pacific Remdesivir (COVID-19) Market is expected to grow at the fastest CAGR from 2023 to 2032. Because of the region's frequent viral disease epidemics, the parent company granted permission for remdesivir production there. Moreover, In the Asia-Pacific region, the Indian Remdesivir (COVID 19) market had the quickest rate of growth while China's Remdesivir (COVID 19) market had the greatest market share.
Leading industry companies are making significant R&D investments in order to diversify their product offerings, which will drive the Remdesivir (COVID-19) market's expansion. Important market developments include new product releases, contractual agreements, mergers and acquisitions, greater investments, and collaboration with other organizations. Market participants are also engaging in a number of strategic actions to increase their global footprint. The Remdesivir (COVID 19) sector needs to provide affordable products if it wants to grow and thrive in a more competitive and challenging market environment.
One of the primary business strategies employed by manufacturers in the worldwide Remdesivir (COVID 19) industry to assist customers and expand the market sector is local manufacturing to reduce operational costs. Some of the biggest benefits to medicine have recently come from the Remdesivir (COVID 19) sector. Major players in the Remdesivir (COVID 19) market, including Gilead Sciences, Inc. (US), Mylan (US), Cipla (India), Hetero Labs (India), and Jubilant Life Sciences (India), and others, are attempting to increase market demand by investing in research and development operations.
Active pharmaceutical ingredients (APIs), generic pharmaceuticals, and branded treatments are all produced and distributed by a pharmaceutical company by the name of Cipla Ltd. (Cipla). It offers solutions for diseases like HIV/AIDS, diabetes, hepatitis, critical care, neurological problems, ophthalmic, cancer, malaria, respiratory and urological problems, osteoporosis, and women's health, as well as cardiovascular and pediatric illnesses. The company also works in consumer healthcare and biosimilars. Cipla also conducts research and development to discover novel medications and medication administration techniques in addition to providing metered-dose inhaler equipment, spacers, and related devices. The company conducts business in a number of significant regulated and developing markets, including South Africa, the US, Canada, and India. Cipla's corporate headquarters are in Mumbai, Maharashtra, India.
Gilead Sciences Inc. (Gilead) is a biopharmaceutical firm with a research-based foundation. It is involved in the research, creation, and marketing of drugs for the management of HIV infection, cardiovascular, haematological, respiratory, and inflammatory diseases of the liver, as well as cancer. The company sells its products through partners and distributors across Europe, the Americas, Asia-Pacific, the Middle East, and Africa. In addition to other locations, it has production facilities in Oceanside, California, Foster City, Ireland, and Cork, Ireland. The company works with academic institutions, medical research facilities, and significant global pharmaceutical companies to develop new treatments. Gilead has its headquarters in the US city of Foster City.
· Gilead Sciences, Inc. (US)
· Mylan (US)
· Cipla (India)
· Hetero Labs (India)
· Jubilant Life Sciences (India)
April 2021: The production of remdesivir at India's Cipla Ltd (CIPL.NS) has grown to help meet "unprecedented demand" as the country battles a significant second wave of infections.
· 5mg
· 10mg
· 50mg
· 100mg
· Hospitals
· Drug stores
· Others
· North America
- U.S.
- Canada
· Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
· Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
· Rest of the World
- Middle East
- Africa
- Latin America
Report Scope
|
Report Attribute/Metric |
Details |
|
Market Size 2022 |
USD 5.7 Billion |
|
Market Size 2023 |
USD 5.8 Billion |
|
Market Size 2032 |
USD 10.80 Billion |
|
Compound Annual Growth Rate (CAGR) |
7.80% (2023-2032) |
|
Base Year |
2022 |
|
Market Forecast Period |
2023-2032 |
|
Historical Data |
2018- 2022 |
|
Market Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
Dosage, Distribution Channel, and Region |
|
Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
|
Countries Covered |
The U.S., Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
|
Key Companies Profiled |
Gilead Sciences, Inc. (US), Mylan (US), Cipla (India), Hetero Labs (India), and Jubilant Life Sciences (India) |
|
Key Market Opportunities |
Obesity in children, healthier and more balanced diets |
|
Key Market Dynamics |
Increase in health difficulties and worries, leading in costly operations |
The global Remdesivir (COVID 19) Market was valued at USD 5.7 billion in 2022, and it is estimated to reach USD 10.80 billion by 2032.
The global market is projected to grow at a CAGR of 7.80% during the forecast period, 2023-2032.
North America had the largest share in the global market
The key players in the market are General Mills Inc., Amway, Conagra Brands Inc., Cargill Incorporated, Abbott Laboratories, Kraft Foods Group Inc., The Coca-Cola Company.
The beverage category dominated the market in 2022.
The store based had the largest share in the global market.
Research on the market is done by industry professionals who provide personalized insights on the industry structure, market segmentation, Type assessment, competitive landscape (CL), along with penetration, and emerging trends. In addition to years of professional experience in their various fields and sectors, their analysis is largely based on primary interview (60%) and secondary research (40%) as well as years of professional experience. In addition, our researchers forecast the market's direction over the following seven years by examining past trends and the market's current position. Additionally, various trends of segments and categories that are geographically portrayed are studied and estimated using primary and secondary research.
The key level executives (VP, CEO, Marketing Directors, and Business Development Managers) of the major industry participants who are active and prominent as well as mid-scale businesses operating in this market were interviewed in-depth for this supply-side report by overall Global Market Research.
Extensive primary research was conducted to gain a deeper grasp of the market and industry. Both primary and secondary research, as well as years of pertinent professional experience, are used to support the analysis. By analyzing past and present market patterns, our experts were able to forecast the market's course over the following seven years. For the geographically offered categories in the list of market tables, it differs per category. In connection with the Global Market research report, we also conducted a number of primary interviews with senior level executives (VP, CEO's, Directors, Marketing Directors, Business Development Managers, CFOs, Technical Consultants, Key Opinion Leaders, Industry Experts, Decision Matrix Authorities, and other crucial individuals) of the key industry players who dominated the Global market.
The primary purpose of secondary research was to gather, identify, and validate the information necessary for the thorough, technical, market-focused, and commercial analysis of the global market. With the use of this study, it was also possible to classify and segment the market in accordance with market trends, geographic markets, and regional considerations linked to market type. Analysts have gathered data in the Distribution Channel for the study of the market from reliable sources including annual reports, journals, white papers, corporate presentations, company websites, international organizations of Energy and Power manufacturers, credible paid databases, and many others to gather reliable intel.
Both top-down and bottom-up methodologies were employed to assess the accuracy of the global market size. The market for as a whole was estimated using these methods for a number of different dependent submarkets. Secondary research was used to address the major industry players, and primary and secondary research was used to calculate their market shares in the various regions. This complete intellectual process includes reading the annual and financial reports of the top market participants and conducting in-depth interviews with top industry executives (VP, CEO, Marketing Directors, and Business Development Managers) to gain important industry insights.
Through reliable secondary sources and validated primary sources, the classification of the global markets and their geographic percentage splits were established. To obtain the final qualitative and quantitative data, all relevant variables that might have an impact on the market under investigation have been taken into consideration, inspected in great depth, verified through primary research, and assessed. This information was collected, added to, and thoroughly examined by professional analysts before being provided in this report. The process used to estimate the overall market size for this study is depicted in the following image as an example.
Report Code :
RL65244
Published on :
Sep 2023
Request a Free Sample Report
Speak to Analyst